MCID: MLG070
MIFTS: 37

Malignant Iris Melanoma

Categories: Cancer diseases, Eye diseases, Neuronal diseases, Skin diseases

Aliases & Classifications for Malignant Iris Melanoma

MalaCards integrated aliases for Malignant Iris Melanoma:

Name: Malignant Iris Melanoma 12 15
Malignant Melanoma of Iris 12
Melanoma of the Iris 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6994
NCIt 51 C9088
UMLS 74 C0346373

Summaries for Malignant Iris Melanoma

MalaCards based summary : Malignant Iris Melanoma, also known as malignant melanoma of iris, is related to melanoma, uveal and iris spindle cell melanoma. An important gene associated with Malignant Iris Melanoma is S100B (S100 Calcium Binding Protein B), and among its related pathways/superpathways are Integrated Breast Cancer Pathway and TGF-beta Signaling Pathway (WikiPathways). The drugs Melphalan and Fotemustine have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and skin, and related phenotype is normal.

Related Diseases for Malignant Iris Melanoma

Diseases related to Malignant Iris Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Related Disease Score Top Affiliating Genes
1 melanoma, uveal 11.3
2 iris spindle cell melanoma 11.2
3 epidermoid cysts 10.1 S100A1 S100B
4 intraneural perineurioma 10.1 S100A1 S100B
5 myoepithelioma 10.1 S100A1 S100B
6 ischemic fasciitis 10.1 CCND1 S100A1
7 chordoma 10.1 S100A1 S100B
8 chondromyxoid fibroma 10.1 CCND1 S100A1
9 amelanotic melanoma 10.0
10 malignant giant cell tumor 10.0 S100B TP53
11 chordoid glioma 10.0 S100B TP53
12 spiradenoma 10.0 S100B TP53
13 microglandular adenosis 10.0 S100B TP53
14 papilloma of choroid plexus 9.9 S100B TP53
15 myxosarcoma 9.9 S100A1 TP53
16 embryonal sarcoma 9.9 S100B TP53
17 cerebral primitive neuroectodermal tumor 9.9 S100B TP53
18 bile duct adenocarcinoma 9.9 S100A1 TP53
19 optic nerve glioma 9.9 S100B TP53
20 melanoma 9.9
21 ganglioglioma 9.9 S100B TP53
22 non-proliferative fibrocystic change of the breast 9.9 CCND1 TP53
23 synchronous bilateral breast carcinoma 9.9 CCND1 TP53
24 pleomorphic adenoma 9.9 S100B TP53
25 oral leukoplakia 9.9 CCND1 TP53
26 cll/sll 9.9 CCND1 TP53
27 dermatofibrosarcoma protuberans 9.9 S100B TP53
28 papilloma 9.9 CCND1 TP53
29 verrucous carcinoma 9.9 CCND1 TP53
30 mutagen sensitivity 9.9 CCND1 TP53
31 pre-malignant neoplasm 9.9 CCND1 TP53
32 keratocystic odontogenic tumor 9.9 CCND1 TP53
33 laryngeal disease 9.9 CCND1 TP53
34 oropharynx cancer 9.9 CCND1 TP53
35 pharynx cancer 9.9 CCND1 TP53
36 intestinal benign neoplasm 9.9 CCND1 TP53
37 inverted papilloma 9.9 CCND1 TP53
38 penile cancer 9.9 CCND1 TP53
39 nasopharyngeal disease 9.9 CCND1 TP53
40 retinal cancer 9.9 CCND1 TP53
41 atypical teratoid rhabdoid tumor 9.9 CCND1 TP53
42 gliosarcoma 9.9 S100B TP53
43 esophageal disease 9.9 CCND1 TP53
44 cervix disease 9.9 CCND1 TP53
45 estrogen-receptor positive breast cancer 9.9 CCND1 TP53
46 ocular cancer 9.9 CCND1 TP53
47 basal cell nevus syndrome 9.9
48 xeroderma pigmentosum, variant type 9.9
49 iridocorneal endothelial syndrome 9.9
50 nevus of ota 9.9

Graphical network of the top 20 diseases related to Malignant Iris Melanoma:



Diseases related to Malignant Iris Melanoma

Symptoms & Phenotypes for Malignant Iris Melanoma

MGI Mouse Phenotypes related to Malignant Iris Melanoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 8.92 CCND1 S100A1 S100B TP53

Drugs & Therapeutics for Malignant Iris Melanoma

Drugs for Malignant Iris Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Melphalan Approved Phase 3,Phase 2 148-82-3 460612 4053
2
Fotemustine Experimental, Investigational Phase 3
3 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
4 Alkylating Agents Phase 3,Phase 2,Phase 1
5 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
6 Immunologic Factors Phase 3,Phase 2,Phase 1,Early Phase 1
7 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
9
Bevacizumab Approved, Investigational Phase 2 216974-75-3
10
Sodium Citrate Approved, Investigational Phase 2 68-04-2
11
Cisplatin Approved Phase 2 15663-27-1 441203 84093 2767
12
Sunitinib Approved, Investigational Phase 2,Phase 1 557795-19-4, 341031-54-7 5329102
13
Tamoxifen Approved Phase 2 10540-29-1 2733526
14
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
15
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
16
Carboplatin Approved Phase 2 41575-94-4 38904 10339178 498142
17
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
18
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
19
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
20
Sargramostim Approved, Investigational Phase 2,Phase 1 123774-72-1, 83869-56-1
21
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
22
Ipilimumab Approved Phase 2,Phase 1,Early Phase 1 477202-00-9
23
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
24
Aluminum sulfate Approved Phase 2 10043-01-3
25
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
26
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
27
Pancrelipase Approved, Investigational Phase 2 53608-75-6
28
Iodine Approved, Investigational Phase 2,Phase 1 7553-56-2 807
29
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
30
Acetaminophen Approved Phase 2 103-90-2 1983
31
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
32
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
33
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
34
Promethazine Approved, Investigational Phase 2 60-87-7 4927
35
Lenalidomide Approved Phase 2 191732-72-6 216326
36
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
37
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
38
Imidazole Experimental, Investigational Phase 2 288-32-4 795
39
SB-649868 Experimental, Investigational Phase 2 110-16-7, 110-17-8 444972
40
Cediranib Investigational Phase 2 288383-20-0 9933475
41 Pancreatic Polypeptide Investigational Phase 2,Phase 1 59763-91-6
42 Antineoplastic Agents, Immunological Phase 2,Phase 1,Early Phase 1
43 Angiogenesis Modulating Agents Phase 2,Phase 1
44 Angiogenesis Inhibitors Phase 2,Phase 1
45 Bone Density Conservation Agents Phase 2
46 Protein Kinase Inhibitors Phase 2,Phase 1
47 Estrogen Receptor Antagonists Phase 2
48 Estrogen Antagonists Phase 2
49 Hormones Phase 2,Phase 1
50 Citrate Phase 2

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
2 Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma Terminated NCT00110123 Phase 3 fotemustine;isolated perfusion
3 Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Unknown status NCT01217398 Phase 2 temozolomide
4 Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2 cisplatin;sunitinib malate;tamoxifen citrate
5 Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance Completed NCT01100528 Phase 2 dacarbazine
6 Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye Completed NCT00329641 Phase 2 carboplatin;paclitaxel;sorafenib tosylate
7 Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
8 Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01413191 Phase 2
9 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery Completed NCT00738361 Phase 2 nab-paclitaxel
10 Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma Completed NCT00288041 Phase 2 carboplatin;paclitaxel;bortezomib
11 VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00450255 Phase 2
12 Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma Completed NCT00121225 Phase 2 vorinostat
13 Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma Completed NCT00089063 Phase 2 Montanide ISA 51 VG
14 Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma Completed NCT00085189 Phase 2 Montanide ISA 51 VG;agatolimod sodium
15 AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma Completed NCT00243061 Phase 2 cediranib maleate
16 Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00027742 Phase 2 temozolomide
17 Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma Completed NCT00085306 Phase 2
18 Vaccine Therapy in Treating Patients With Metastatic Melanoma Completed NCT00334776 Phase 2
19 PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma Completed NCT00238329 Phase 2 thalidomide
20 Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma Completed NCT00003802 Phase 2 pyrazoloacridine
21 Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma Completed NCT00032045 Phase 2
22 Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma Completed NCT00031733 Phase 2 alum adjuvant
23 Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00005815 Phase 1, Phase 2 temozolomide;thalidomide
24 Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma Completed NCT00072345 Phase 2 lomustine;temozolomide;thalidomide
25 Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma Completed NCT00058279 Phase 1, Phase 2
26 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery Completed NCT00089206 Phase 2
27 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma Completed NCT00084656 Phase 2
28 Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma Completed NCT00089219 Phase 1, Phase 2
29 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
30 Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma Recruiting NCT02068586 Phase 2 Sunitinib;Valproic Acid
31 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
32 Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma Terminated NCT00482911 Phase 2 cyclophosphamide;lenalidomide;sunitinib malate
33 Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery Completed NCT00025181 Phase 1
34 Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma Completed NCT01005472 Phase 1 sunitinib malate;temozolomide
35 Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00471471 Phase 1
36 Vaccine Therapy in Treating Patients With Advanced Melanoma Completed NCT00705640 Phase 1
37 Dendritic Cell Vaccination During Lymphoid Reconstruction Completed NCT00313508 Phase 1 Fludarabine
38 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
39 Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Completed NCT00003022 Phase 1
40 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Terminated NCT00005841 Phase 1
41 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
42 Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye Completed NCT00952939
43 Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases Terminated NCT02336763 Not Applicable
44 Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases Terminated NCT01730157 Early Phase 1
45 Validation of a Molecular Prognostic Test for Eye Melanoma Withdrawn NCT00406120

Search NIH Clinical Center for Malignant Iris Melanoma

Genetic Tests for Malignant Iris Melanoma

Anatomical Context for Malignant Iris Melanoma

MalaCards organs/tissues related to Malignant Iris Melanoma:

42
Eye, Liver, Skin, Bone, Testes, Endothelial

Publications for Malignant Iris Melanoma

Articles related to Malignant Iris Melanoma:

# Title Authors Year
1
Ultrasound biomicroscopy in management of malignant iris melanoma. ( 12742854 )
2003
2
Diffuse malignant melanoma of iris with metastases. ( 2038723 )
1991
3
Diffuse malignant melanoma of iris with metastases. ( 2183381 )
1990
4
Diffuse malignant melanoma of iris; report of cases. ( 18119671 )
1949
5
Malignant melanoma of iris and ciliary body. ( 21000630 )
1946

Variations for Malignant Iris Melanoma

Expression for Malignant Iris Melanoma

Search GEO for disease gene expression data for Malignant Iris Melanoma.

Pathways for Malignant Iris Melanoma

GO Terms for Malignant Iris Melanoma

Biological processes related to Malignant Iris Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.33 CCND1 S100A1 TP53
2 cellular response to hypoxia GO:0071456 9.26 S100B TP53
3 response to glucocorticoid GO:0051384 8.96 CCND1 S100B
4 mitotic G1 DNA damage checkpoint GO:0031571 8.62 CCND1 TP53

Molecular functions related to Malignant Iris Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 histone deacetylase binding GO:0042826 9.16 CCND1 TP53
2 calcium-dependent protein binding GO:0048306 8.96 S100A1 S100B
3 S100 protein binding GO:0044548 8.62 S100A1 S100B

Sources for Malignant Iris Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....